InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（6 笔）
内部人交易记录
董事已披露买入
0
已披露卖出
6
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the complete record of transactions filed by Pyott David e I, 董事. Insider active across 3 companies, notably Biomarin Pharmaceutical INC. In total, 18 reports have been published. Breakdown: 0 buy · 6 sells. Total volume traded: €3m. Activity tracked since 25 May 2021. The latest transaction was disclosed on 1 June 2026 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Pyott David e I
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报18 总计
3,830 股0Common StockSEC:0001178670-26-000048:0
921 股@ US$297.710.0006% mcap4.6% 占其流量Common StockSEC:0001178670-26-000048:1
1,175 股@ US$298.910.0008% mcap5.9% 占其流量Common StockSEC:0001178670-26-000048:2
1,222 股@ US$299.870.0008% mcap6.2% 占其流量Common StockSEC:0001178670-26-000048:3
495 股@ US$300.720.0003% mcap2.5% 占其流量Common StockSEC:0001178670-26-000048:4
17 股@ US$302.650.0000% mcap0.1% 占其流量Common StockSEC:0001178670-26-000048:5
671 股0Common StockSEC:0001178670-26-000039:0
1,383 股Common StockSEC:0001051578-26-000006:0
775 股0Common StockSEC:0001735276-25-000063:0
7,440 股@ US$299.0040.2% 占其流量Common StockSEC:0001735276-25-000040:1
7,440 股@ US$88.9512.0% 占其流量Common StockSEC:0001735276-25-000040:0
17,560 股@ US$88.9528.5% 占其流量Common StockSEC:0001735276-24-000070:0
4,720 股0Common StockSEC:0001048477-24-000110:0
4,190 股0Common StockSEC:0001209191-23-031977:0
136 股0Common StockSEC:0001735276-23-000018:0
4,980 股0Common StockSEC:0001567619-22-011800:0
5,120 股0Common StockSEC:0001567619-21-011320:0
2,100 股Common StockSEC:0001140361-16-046894:0
18 条申报中的 18 条
About Pyott David e I
PYOTT DAVID E I is an Administrateur and has 18 filings in total. In the recent filings available, there are no buys and EUR 3,039,559 of sells, mainly in ALNYLAM PHARMACEUTICALS, INC., between 2016-01-06 and 2026-06-03. He is also a director of Biomarín Pharmaceutical INC and Tarsus Pharmaceuticals, Inc.
